Enanta Pharmaceuticals (ENTA) Expected to Post Earnings of $0.87 Per Share


Equities analysts forecast that Enanta Pharmaceuticals (NASDAQ:ENTA) will report earnings of $0.87 per share for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Enanta Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at $0.68 and the highest estimate coming in at $1.05. Enanta Pharmaceuticals posted earnings per share of ($0.44) during the same quarter last year, which would suggest a positive year-over-year growth rate of 297.7%. The company is expected to issue its next earnings results on Monday, August 6th.


On average, analysts expect that Enanta Pharmaceuticals will report full year earnings of $2.97 per share for the current fiscal year, with EPS estimates ranging from $2.39 to $3.55. For the next year, analysts anticipate that the business will report earnings of $2.77 per share, with EPS estimates ranging from $1.86 to $3.67. Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Enanta Pharmaceuticals.

Get Enanta Pharmaceuticals alerts:

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings data on Tuesday, May 8th. The biotechnology company reported $0.61 EPS for the quarter, beating analysts’ consensus estimates of $0.53 by $0.08. Enanta Pharmaceuticals had a return on equity of 18.50% and a net margin of 31.60%. The company had revenue of $44.00 million during the quarter, compared to the consensus estimate of $40.77 million. During the same quarter in the prior year, the firm earned ($0.28) EPS. The company’s quarterly revenue was up 388.9% compared to the same quarter last year.


ENTA has been the subject of a number of recent research reports. Zacks Investment Research downgraded Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, January 30th. ValuEngine upgraded Enanta Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Monday, April 2nd. BidaskClub downgraded shares of Enanta Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 10th. Royal Bank of Canada boosted their target price on shares of Enanta Pharmaceuticals to $78.00 and gave the company a “sector perform” rating in a research note on Thursday, February 8th. Finally, JPMorgan Chase downgraded shares of Enanta Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research note on Thursday, February 8th. Three analysts have rated the stock with a hold rating, one has assigned a buy rating and three have assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $63.60.


In other Enanta Pharmaceuticals news, VP Nathalie Adda sold 4,225 shares of the business’s stock in a transaction on Monday, April 16th. The shares were sold at an average price of $85.58, for a total transaction of $361,575.50. Following the sale, the vice president now directly owns 10,225 shares of the company’s stock, valued at approximately $875,055.50. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Treasurer Paul J. Mellett sold 9,000 shares of the business’s stock in a transaction on Monday, March 19th. The shares were sold at an average price of $86.48, for a total transaction of $778,320.00. Following the sale, the treasurer now directly owns 96,458 shares in the company, valued at $8,341,687.84. The disclosure for this sale can be found here. 10.56% of the stock is owned by insiders.


A number of large investors have recently made changes to their positions in the business. Teachers Advisors LLC raised its stake in Enanta Pharmaceuticals by 3.0% during the 4th quarter. Teachers Advisors LLC now owns 28,668 shares of the biotechnology company’s stock valued at $1,682,000 after purchasing an additional 825 shares during the period. Aperio Group LLC increased its stake in shares of Enanta Pharmaceuticals by 14.1% in the first quarter. Aperio Group LLC now owns 7,288 shares of the biotechnology company’s stock worth $590,000 after acquiring an additional 899 shares during the last quarter. Eqis Capital Management Inc. increased its stake in shares of Enanta Pharmaceuticals by 3.3% in the fourth quarter. Eqis Capital Management Inc. now owns 31,099 shares of the biotechnology company’s stock worth $1,825,000 after acquiring an additional 997 shares during the last quarter. Cubist Systematic Strategies LLC increased its stake in shares of Enanta Pharmaceuticals by 27.0% in the first quarter. Cubist Systematic Strategies LLC now owns 5,850 shares of the biotechnology company’s stock worth $473,000 after acquiring an additional 1,243 shares during the last quarter. Finally, New York State Teachers Retirement System increased its stake in shares of Enanta Pharmaceuticals by 3.4% in the first quarter. New York State Teachers Retirement System now owns 39,790 shares of the biotechnology company’s stock worth $3,219,000 after acquiring an additional 1,300 shares during the last quarter. 74.03% of the stock is currently owned by institutional investors.


Shares of NASDAQ:ENTA opened at $104.65 on Wednesday. Enanta Pharmaceuticals has a one year low of $101.89 and a one year high of $105.57. The firm has a market cap of $1.97 billion, a PE ratio of 36.37 and a beta of 1.05.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus.

Get a free copy of the Zacks research report on Enanta Pharmaceuticals (ENTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com